| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | embelin | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.002 | 0.9 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.0018 | 0.9 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0021 | 1 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.0022 | 1 |